| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 14.79% | Needham | → $17 | Reiterates | Buy → Buy |
| 07/18/2023 | 14.79% | Needham | → $17 | Reiterates | Buy → Buy |
| 07/13/2023 | -25.73% | Morgan Stanley | $8 → $11 | Maintains | Equal-Weight |
| 07/13/2023 | 1.28% | Keybanc | $12 → $15 | Maintains | Overweight |
| 07/12/2023 | 14.79% | Needham | → $17 | Reiterates | Buy → Buy |
| 07/12/2023 | 122.82% | Berenberg | $33 → $33 | Reiterates | Buy → Buy |
| 05/09/2023 | 14.79% | Needham | → $17 | Reiterates | → Buy |
| 05/09/2023 | -18.97% | Keybanc | $20 → $12 | Maintains | Overweight |
| 04/18/2023 | 14.79% | Needham | → $17 | Reiterates | → Buy |
| 03/16/2023 | 14.79% | Needham | → $17 | Initiates Coverage On | → Buy |
| 01/23/2023 | -45.98% | SVB Leerink | $9 → $8 | Maintains | Market Perform |
| 11/09/2022 | -39.23% | Goldman Sachs | $8 → $9 | Maintains | Neutral |
| 10/25/2022 | -39.23% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 09/16/2022 | 35.04% | Keybanc | → $20 | Initiates Coverage On | → Overweight |
| 08/11/2022 | -45.98% | Goldman Sachs | $7 → $8 | Maintains | Neutral |
| 05/24/2022 | -52.73% | Goldman Sachs | $9 → $7 | Maintains | Neutral |
| 05/12/2022 | -39.23% | Goldman Sachs | $10 → $9 | Maintains | Neutral |
| 04/18/2022 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 03/24/2022 | -32.48% | Goldman Sachs | $32 → $10 | Maintains | Neutral |
| 03/04/2022 | -32.48% | SVB Leerink | $32 → $10 | Downgrades | Outperform → Market Perform |
| 12/08/2021 | 116.07% | SVB Leerink | $30 → $32 | Maintains | Outperform |
| 09/21/2021 | 149.83% | Berenberg | → $37 | Initiates Coverage On | → Buy |
| 08/16/2021 | 102.57% | SVB Leerink | $33 → $30 | Maintains | Outperform |
| 05/11/2021 | 122.82% | SVB Leerink | → $33 | Initiates Coverage On | → Outperform |
| 05/11/2021 | 109.32% | B of A Securities | → $31 | Initiates Coverage On | → Buy |
| 05/11/2021 | 116.07% | JP Morgan | → $32 | Initiates Coverage On | → Neutral |
| 05/11/2021 | 129.57% | Goldman Sachs | → $34 | Initiates Coverage On | → Neutral |
| 05/11/2021 | 143.08% | Keybanc | → $36 | Initiates Coverage On | → Overweight |
What is the target price for Recursion Pharmaceuticals (RXRX)?
The latest price target for Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on July 21, 2023. The analyst firm set a price target for $17.00 expecting RXRX to rise to within 12 months (a possible 14.79% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Recursion Pharmaceuticals (RXRX)?
The latest analyst rating for Recursion Pharmaceuticals (NASDAQ: RXRX) was provided by Needham, and Recursion Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Recursion Pharmaceuticals (RXRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Recursion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Recursion Pharmaceuticals was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
Is the Analyst Rating Recursion Pharmaceuticals (RXRX) correct?
While ratings are subjective and will change, the latest Recursion Pharmaceuticals (RXRX) rating was a reiterated with a price target of $0.00 to $17.00. The current price Recursion Pharmaceuticals (RXRX) is trading at is $14.81, which is within the analyst's predicted range.